Affiliations: [a] Molecular Gerontology Laboratory, Department of Biochemistry, Bharathidasan University, Tiruchirappalli, Tamilnadu, India
| [b] Department of Bioinformatics, Bharathidasan University, Tiruchirappalli, Tamilnadu, India
| [c] UGC-Faculty Recharge Program (UGC-FRP), University Grant Commission, Laboratory of Stem Cells and Neurodegeneration, Department of Animal Science, Bharathidasan University, Tiruchirappalli, Tamilnadu, India
Correspondence:
[*]
Correspondence to: Dr. M. Anusuyadevi, Department of Biochemistry, Molecular Gerontology Laboratory, Bharathidasan University, Tiruchirappalli-620024, Tamilnadu, India. Tel.: +91 431 2407071/Ext.438; Fax: +91 431 2407045; E-mail: msanushyas2005@gmail.com.
Abstract: Deterioration of cholesterol metabolism has recently been a frontier subject of investigation in the field of Alzheimer’s disease (AD). Though amyloid-β protein precursor (AβPP) primes the pathological cascade, changes in cholesterol levels and its intermediates, geranyl geranyl pyrophosphate and farnesyl pyrophosphate, is expected to have a different consequence on AβPP processing and amyloid-β (Aβ) generation. However, the use of statins (HMG-COA reductase inhibitor) has been widely implicated in slowing down the pathogenic progression of AD, while the epidemiological reports on its biological effect remains controversial. Considering this fact, the choice of drug that could maintain cholesterol homeostasis without altering its biosynthesis may yield a better therapeutic efficacy on AD. Thus, the present study focused on determining the influence of cholesterol and isoprenoids on amyloidogenic-cleavage of AβPP, in addition to resveratrol as a potent therapeutic drug in CHO-APPswe cell lines. High levels of cholesterol were found to enhance the maturation of AβPP and altered the expression and subcellular localization of ADAM10, BACE1, and PS1 thereby promoting Aβ generation, whereas high isoprenoids increased both maturation as well as amyloidogenic-cleavage of AβPP, which was evident through β-CTF production. Interestingly, the therapeutic efficacy of resveratrol maintained cholesterol homeostasis and reduced the amyloidogenic burden through its ability to enhance SIRT1 expression and thereby regulating differential expression of AD determinants.
